Take part in a paid clinical trial

We are conducting a clinical trial to explore a potential new treatment for weight management and metabolic disorders. This treatment is being developed to support healthy weight loss while helping the body maintain lean muscle mass, which plays an important role in long-term weight maintenance. Through this study, we hope to better understand whether this new approach can provide a safe and effective option for people who may benefit from additional support with managing their weight. By joining the trial, you’ll be contributing to important research that could help improve weight management options in the future.

This study is testing a new drug that is being developed to help people with inflammatory bowel disease (IBD), including ulcerative colitis and Crohn’s disease. While there are treatments already available, many of them only target one part of the immune system and don’t fully address all aspects of the disease. For example, current therapies often don’t treat the scarring (called fibrosis) that can build up in the bowel over time, and they may not fully heal the lining of the gut. Some treatments also stop working after a while or cause side effects that make long-term use difficult.

This study is exploring a potential new therapy aimed at helping slow disease progression and improve outcomes for people living with idiopathic pulmonary fibrosis. This research is made possible with Healthy Volunteers.

Idiopathic pulmonary fibrosis, or IPF, is a long-term lung condition where the tissue in the lungs slowly becomes scarred and stiff.

Normally, your lungs are soft and stretchy, which makes it easy to breathe and for oxygen to pass into your blood. With IPF, scar tissue builds up in the lungs over time, making them thicker and harder. As this scarring increases, it becomes more difficult to breathe and harder for the body to get the oxygen it needs.

The purpose of this study is to evaluate how the experimental drug is processed in the body and to assess potential interactions between the study drug and medications currently approved for idiopathic pulmonary fibrosis (IPF).

This clinical trial is sponsored by a pharmaceutical company. It is investigating a potential drug (the study drug) for inflammatory and fibrotic conditions. These include long-term digestive diseases such as ulcerative colitis and Crohn’s disease, where ongoing inflammation and scarring can damage the intestines. Some current treatments may not work for everyone and can cause significant side effects. This trial is designed to assess the safety and potential benefits of an investigational study drug that may offer an additional option for people who do not respond well to existing therapies. This trial is being held in Melbourne.